AI assistant
Vaxcyte, Inc. — Director's Dealing 2022
Mar 5, 2022
31100_dirs_2022-03-04_0de3f703-55ae-4354-87ab-a73b96c0c5b4.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Vaxcyte, Inc. (PCVX)
CIK: 0001649094
Period of Report: 2022-03-02
Reporting Person: Wassil Jim (Chief Operating Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2022-03-02 | Common Stock | A | 25000 | $0.00 | Acquired | 42944 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2022-03-02 | Stock Option (right to buy) | $24.79 | A | 100000 | Acquired | 2032-03-01 | Common Stock (100000) | Direct |
| 2022-03-02 | Stock Option (right to buy) | $24.79 | A | 150000 | Acquired | 2032-03-01 | Common Stock (150000) | Direct |
Footnotes
F1: Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs vest as to 25% of the shares subject to the award on September 2, 2022 and 12.5% of the shares every six months thereafter.
F2: 12/48 of shares subject to the option vest on February 15, 2023, and 1/48 of the shares vest monthly thereafter.
F3: 1/48 of shares subject to the option vest on April 2, 2022, and 1/48 of the shares vest monthly thereafter.